deferoxamine has been researched along with Brain Hemorrhage, Cerebral, Traumatic in 2 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, J | 1 |
| Yuan, Q | 1 |
| Sun, YR | 1 |
| Wu, X | 1 |
| Du, ZY | 1 |
| Li, ZQ | 1 |
| Wu, XH | 1 |
| Zhou, LF | 1 |
| Wu, G | 1 |
| Hu, J | 1 |
| Gu, Y | 1 |
| Hua, Y | 1 |
| Keep, RF | 1 |
| Morgenstern, LB | 1 |
| Xi, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage[NCT02367248] | Phase 1/Phase 2 | 180 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| Futility Study of Deferoxamine in Intracerebral Hemorrhage[NCT01662895] | Phase 2 | 42 participants (Actual) | Interventional | 2013-03-18 | Terminated (stopped due to By DSMB on October 18, 2013 due to increased incidence of ARDS. See modified protocol [NCT02175225) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mortality at any time from randomization through day-90 (NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 3 |
| Normal Saline | 0 |
(NCT01662895)
Timeframe: within 7 days or discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 1 |
| Normal Saline | 1 |
(NCT01662895)
Timeframe: within 7 days or discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 0 |
| Normal Saline | 1 |
(NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 9 |
| Normal Saline | 6 |
(NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 6 |
| Normal Saline | 0 |
(NCT01662895)
Timeframe: within 7 days or discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 0 |
| Normal Saline | 0 |
"The primary outcome measure of efficacy is the modified Rankin Scale (mRS) score, dichotomized to define good functional outcome as mRS 0-2 at 90 days.~The minimum mRS score is 0 (i.e. no disability). The maximum score is 6 (i.e. dead)." (NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 6 |
| Normal Saline | 10 |
The proportion of DFO- and placebo-treated subjects with mRS 0-3 vs. 4-6 at 90 days (NCT01662895)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Deferoxamine | 12 |
| Normal Saline | 14 |
1 trial available for deferoxamine and Brain Hemorrhage, Cerebral, Traumatic
| Article | Year |
|---|---|
Effects of Deferoxamine Mesylate on Hematoma and Perihematoma Edema after Traumatic Intracerebral Hemorrhage.
Topics: Adult; Aged; Brain Edema; Cerebral Hemorrhage, Traumatic; Deferoxamine; Female; Humans; Male; Middle | 2017 |
1 other study available for deferoxamine and Brain Hemorrhage, Cerebral, Traumatic
| Article | Year |
|---|---|
Deferoxamine reduces intracerebral hematoma-induced iron accumulation and neuronal death in piglets.
Topics: Animals; Antidotes; Brain; Cell Death; Cerebral Hemorrhage, Traumatic; Deferoxamine; Ferritins; Fluo | 2009 |
Deferoxamine reduces intracerebral hematoma-induced iron accumulation and neuronal death in piglets.
Topics: Animals; Antidotes; Brain; Cell Death; Cerebral Hemorrhage, Traumatic; Deferoxamine; Ferritins; Fluo | 2009 |
Deferoxamine reduces intracerebral hematoma-induced iron accumulation and neuronal death in piglets.
Topics: Animals; Antidotes; Brain; Cell Death; Cerebral Hemorrhage, Traumatic; Deferoxamine; Ferritins; Fluo | 2009 |
Deferoxamine reduces intracerebral hematoma-induced iron accumulation and neuronal death in piglets.
Topics: Animals; Antidotes; Brain; Cell Death; Cerebral Hemorrhage, Traumatic; Deferoxamine; Ferritins; Fluo | 2009 |